{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:22Z","timestamp":1790805862493,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijcard.2020.06.032","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:36:35Z","timestamp":1593218195000},"page":"78-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience"],"prefix":"10.1016","volume":"320","author":[{"given":"Tauseef","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Del Cid","family":"Fratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishanth","family":"Mattumpuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setri","family":"Fugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Uprety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chineme","family":"Nwaichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Golzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ijcard.2020.06.032_bb0005","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.ijcard.2020.06.032_bb0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke."},{"issue":"21","key":"10.1016\/j.ijcard.2020.06.032_bb0015","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2020.06.032_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2020.06.032_bb0025","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation","volume":"44","author":"Harrington","year":"2013","journal-title":"Stroke."},{"issue":"14","key":"10.1016\/j.ijcard.2020.06.032_bb0030","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2020.06.032_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/joa3.12073","article-title":"XANAP: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia","volume":"34","author":"Kim","year":"2018","journal-title":"J. Arrhythmia"},{"issue":"4","key":"10.1016\/j.ijcard.2020.06.032_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ehj.2018.09.002","article-title":"XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America","volume":"70","author":"Martinez","year":"2018","journal-title":"Egypt Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2020.06.032_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.ijcard.2020.06.032_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","article-title":"Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban","volume":"38","author":"Tamayo","year":"2015","journal-title":"Clin. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2020.06.032_bb0055","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jcpt.12288","article-title":"Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital","volume":"40","author":"Tellor","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"issue":"12","key":"10.1016\/j.ijcard.2020.06.032_bb0060","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ijcard.2020.06.032_bb0065","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2174\/1389201019666181112100612","article-title":"In vitro bioaccessibility, bioavailability, and plasma protein interaction of new oral anticoagulants in the presence of macronutrients","volume":"19","author":"Raiola","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"08","key":"10.1016\/j.ijcard.2020.06.032_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH13-02-0150","article-title":"Gastrointestinal bleeding with the new oral anticoagulants\u2013defining the issues and the management strategies","volume":"110","author":"Desai","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"10117","key":"10.1016\/j.ijcard.2020.06.032_bb0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijcard.2020.06.032_bb0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2020.06.032_bb0085","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"10152","key":"10.1016\/j.ijcard.2020.06.032_bb0090","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ijcard.2020.06.032_bb0095","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Group ASCEND","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcard.2020.06.032_bb0100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2020.06.032_bb0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2020.06.032_bb0110","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2020.06.032_bb0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.ijcard.2020.06.032_bb0120","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke."},{"key":"10.1016\/j.ijcard.2020.06.032_bb0125","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"issue":"05","key":"10.1016\/j.ijcard.2020.06.032_bb0130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1160\/TH14-02-0118","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation","volume":"112","author":"Skj\u00f8th","year":"2014","journal-title":"Thromb. Haemost."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320334100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320334100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:48:00Z","timestamp":1759092480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320334100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"alternative-id":["S0167527320334100"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.06.032","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}